Embolic Agent Selection and Outcomes in Renal Angiomyolipoma Embolisation
Journal of Medical Imaging and Radiation Oncology · 2026-08 · 70 (5) · 440-446
DOI: 10.1111/1754-9485.70108 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, online erschienen am 22.04.2026. Verfasst von Ross O'Shea und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Imaging and Interventional Radiology Department, Fiona Stanley Hospital, South Metropolitan Health Service, Perth, WA, Australia. Hauptthemen laut MEDLINE: Angiomyolipoma, Kidney Neoplasms, Embolization, Therapeutic. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate whether embolic agent selection influences outcomes following selective arterial embolisation (SAE) of renal angiomyolipomas (r‐AMLs) and to assess procedural safety and effects on renal function. Materials and Methods A retrospective observational study was performed of all r‐AML SAEs undertaken at a tertiary institution between 2015 and 2024. Change in tumour size on pre‐ and 3–6‐month post‐procedural imaging was the primary outcome. Secondary outcomes included technical success, re‐intervention rates, complications (Clavien–Dindo), renal function change and length of hospital stay. Outcomes were compared across embolic agents including microparticles, liquid embolic agents, coils and combined approaches.
Results
Forty‐nine patients (51 lesions) underwent angiography, with SAE attempted in 54 procedures. Technical success was achieved in 91%. Tumour size reduction occurred in 91% of lesions with follow‐up imaging, with a mean reduction of 1.75 cm ( p < 0.0001). Liquid embolic agents alone demonstrated the greatest mean tumour reduction with a mean reduction of 2.4 cm and a 0% re‐intervention rate. Microparticles alone achieved significant size reduction with a low re‐intervention rate, while coil‐only embolisation was associated with inferior outcomes and higher re‐intervention rates. Combined embolisation strategies achieved significant tumour reduction but did not outperform liquid agents alone. Complications occurred in 10% of patients and were predominantly minor. No patient required renal replacement therapy, and the median eGFR did not change significantly.
Conclusion
SAE is a safe and effective treatment for r‐AML in both elective and emergency settings. Liquid embolic agents achieved the greatest tumour reduction with low re‐intervention rates, while coil‐only embolisation showed inferior outcomes and should be avoided where possible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Imaging and Interventional Radiology Department, Fiona Stanley Hospital, South Metropolitan Health Service, Perth, WA, Australia.
- Radiology Department, Royal Perth Hospital, Perth, WA, Australia.
- Radiology Department, Sir Charles Gairdner Hospital, Perth, WA, Australia.
ORCID-Profile: Ross O'Shea, Himanshu Pendse
Zitieren
APA
O'Shea, R., Pendse, H., Ho, K., Hasan, H., Wal, R. V., Wyk, M. V., Tibballs, J., & Dulku, G. (2026). Embolic Agent Selection and Outcomes in Renal Angiomyolipoma Embolisation. Journal of Medical Imaging and Radiation Oncology, 70(5), 440-446. https://doi.org/10.1111/1754-9485.70108
Vancouver
O'Shea R, Pendse H, Ho K, Hasan H, Wal RV, Wyk MV, et al. Embolic Agent Selection and Outcomes in Renal Angiomyolipoma Embolisation. Journal of Medical Imaging and Radiation Oncology. 2026;70(5):440-446. doi:10.1111/1754-9485.70108
BibTeX
@article{OShea2026,
author = {O'Shea, Ross and Pendse, Himanshu and Ho, Kevin and Hasan, Hasan and Wal, Ross Vander and Wyk, Matthys Van and Tibballs, Jonathan and Dulku, Gurjeet},
title = {Embolic Agent Selection and Outcomes in Renal Angiomyolipoma Embolisation},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2026},
volume = {70},
number = {5},
pages = {440--446},
doi = {10.1111/1754-9485.70108}
}
EUVIMED